Page 131«..1020..130131132133..140..»

Category Archives: Cell Medicine

Massachusetts General researchers discover stem cell that makes eggs

Posted: February 26, 2012 at 7:56 pm

Massachusetts General Hospital researchers reported today they have discovered a rare stem cell in women’s ovaries that they hope one day might be used to make eggs, a claim already generating vigorous debate among scientists familiar with the research.

For decades, it has been thought that women are born with a finite supply of eggs, limiting their reproductive years. Doctors have sought ways of extending the fertility of women, especially as many wait later in life to begin having children.

The research, led by Jonathan Tilly of Mass. General and appearing in the journal Nature Medicine, opens the door to the possibility of taking tissue from a woman’s ovaries, harvesting stem cells from that tissue, and then creating eggs.

But scientists not involved with the Mass. General research said such an approach -- if it is even possible -- sits far in the future and will require considerably more work. Several scientists said Tilly, who co-founded a company focused on developing novel infertility treatments, had not yet made a convincing case that the stem cells he discovered can yield viable eggs, a critical first step.

Tilly has been a lightning rod in the field of fertility medicine since 2004, when he challenged the orthodoxy that women do not produce new eggs. In a research paper published that year, Tilly laid the foundation for the findings reported yesterday.

“There was a lot of backlash. It wasn’t surprising, given the magnitude of the paradigm shift that was being proposed -- this was one of the fundamental beliefs in our field,” Tilly said. “The subsequent eight years have been a long haul.”

In his new study, Tilly extended research by Chinese scientists published in 2009. He developed a technique that allowed scientists to sift out rare stem cells within the ovaries of mice that were tagged and implanted into the ovaries of normal mice. In the mouse ovaries, the stem cells produced eggs, which were removed and fertilized in a laboratory dish. They developed into embryos, although scientists did not use the embryos to produce mice.

Tilly and his team then wanted to know if such cells existed in humans, too.

The research team obtained ovarian tissue removed from young women undergoing sex change operations in Japan and performed the same experiment they’d done with the mouse ovaries. Much to their excitement, they discovered the rare, egg-producing cells in humans.

In later experiments, the human stem cells were used to produce cells that appeared to be eggs. In part because of ethical limitations, researchers were not able to show that the eggs could be used to create human embryos.

Tilly said that he has patented the stem cells and licensed the technology to OvaScience, the startup he co-founded.

Outside researchers described the findings as intriguing and provocative but also raised many questions. Scientists said it was still far from certain that the eggs created in the experiments could be used to produce babies. And they expressed concern that the findings could falsely inflate the hopes of women struggling with infertility.

Dr. David Keefe, chairman of obstetrics and gynecology at New York University Langone Medical Center, said he and other clinicians who see patients would like more than anything to have greater options for women to overcome infertility. But he said the Mass. General researcher had a history of leaping ahead from basic research findings to suggest clinical possibilities.

“Those of us who take care of patients are extremely protective of their hopes,” Keefe said. He noted that a few years ago, he saw half-a-dozen patients who wanted to delay their fertility decisions because of earlier research at Mass. General.

Even if the new findings are immediately replicated in labs around the world, Keefe said, “it’s so far from being clinical that it’s predatory to not be circumspect about it. Humility is an absolute requirement in this field. You’re dealing with people’s hopes and dreams.”

A 2005 study led by Tilly and done in mice suggested bone marrow transplants might offer a way to restore fertility. A year later, a separate group of Harvard researchers showed that this was unlikely to be true. Tilly himself no longer believes this is a way to restore fertility.

“The big difference in that work, now in retrospect, is these non-ovarian sources [of stem cells] don’t appear to do the job,” he said.

Tilly’s work in the past has divided researchers and failed to persuade many in the field that his interpretations are correct.

Teresa Woodruff, a professor of obstetrics and gynecology at the Feinberg School of Medicine at Northwestern University said she had already drawn up a chart of the claims made in the paper, the evidence to support those claims, and the questions they raise. Still, she said, “I do think he’s pushing the envelope in a way that does push all of us to think more broadly.”

Evelyn Telfer, a cell biologist at the University of Edinburgh, who criticized some of Tilly’s earlier work, said she is excited about the new findings. Tilly said that next month, he will fly to Scotland to begin a collaboration with Telfer.

“What he’s saying is we can get these cells,” Telfer said, “and I think it’s pretty convincing.”

The new paper doesn’t offer evidence that such stem cells are active in the ovary, supplying eggs during a woman’s lifetime. But the powerful cells could provide new insights into the important and poorly understood process in biology of egg-formation and allow scientists to look for drugs that might increase the activities of these stem cells, in order to overcome fertility problems.

Skeptics and supporters agreed on one thing: much work lies ahead.

“That’s science,” said Hugh Clarke, a professor in the department of obstetrics and gynecology at McGill University. “Of course, dogma should be challenged, but we shouldn’t assume dogma has been overturned based on a single report.”

Carolyn Y. Johnson can be reached at cjohnson@globe.com. Follow her on Twitter @carolynyjohnson.

Read more:
Massachusetts General researchers discover stem cell that makes eggs

Posted in Cell Medicine | Comments Off on Massachusetts General researchers discover stem cell that makes eggs

Stem Cell Finding Could Expand Women’s Lifetime Supply of Eggs

Posted: February 26, 2012 at 7:56 pm

SUNDAY, Feb. 26 (HealthDay News) -- Researchers report that they've isolated stem cells from adult human ovaries that can mature into eggs that may be capable of fertilization.

The lab findings, which upend longstanding scientific theory, could potentially lead to new reproductive technologies and possibly extend the years of a woman's fertility.

It was long believed that women were born with a lifetime supply of eggs, which was depleted by menopause. But a growing body of research -- including a new paper from Massachusetts General Hospital -- suggests egg production may continue into adulthood. The study is published in the March issue of Nature Medicine.

"Fifty years of thinking, in every aspect of experiments, of interpreting the results, and of the clinical management of ovarian function and fertility in women was dictated by one simple belief that turns out to be incorrect," said lead study author Jonathan Tilly, director of the hospital's Vincent Center for Reproductive Biology. "That belief was the egg cell pool endowed at birth is a fixed entity that cannot be renewed."

Dr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore-LIJ Health System in Manhasset, N.Y., said the study is "exciting" but emphasized the work is still very preliminary.

"This is experimental," Hershlag said. "This is a beginning of perhaps something that could bring in new opportunities, but it's going to be a long time in my estimation until clinically we'll be able to actually have human eggs created from stem cells that make babies."

The same team at Mass General caused a stir in 2004 when it published a paper in Nature reporting that female mice retain the ability to make new egg cells well into adulthood.

In both mice and humans, the vast majority of egg cells die through a process called programmed cell death, or apoptosis, the body's way of eliminating unneeded or damaged cells. For humans, that process is dramatic. Female fetuses have about 6 to 7 million eggs at about 20 weeks' gestation, a little more than 1 million at birth, and about 300,000 by puberty.

Studying mice egg cells and follicles, the tiny sacs in which stem cells become eggs, the Mass General researchers discovered something that didn't make mathematical sense.

Most prior research had focused on counting the healthy eggs in the ovaries, and then made assumptions about how many had died from that, Tilly said. But his lab looked at it the opposite way and focused on cell death.

"We found far too many eggs were dying than could be accounted for by the net change in the healthy egg pool," Tilly said. "We reasoned that maybe the field had missed something." They wondered if stem, or precursor cells, were repopulating the ovaries with new eggs.

Initially, the findings were met with skepticism, according to the study authors, but subsequent research bolstered the conclusions.

Those included a 2009 study from a team in China, published in Nature Cell Biology, that isolated, purified and cultured egg stem cells from adult mice, and subsequently introduced them into mice ovaries that were rendered infertile. The infertile mice eventually produced mature oocytes that were fertilized and developed into healthy baby mice.

Studies showing that women had the same capacity as mice were lacking, however.

In this study, Tilly's team used tissue from Japanese women in their 20s and 30s with gender identity disorder, who had their ovaries removed as part of gender reassignment surgery.

The researchers isolated the egg precursor cells and inserted into them a gene from a jellyfish that glows green, then inserted the treated cells into biopsied human ovarian tissue. They then transplanted the human tissue into mice. The green fluorescence allowed researchers to see that the stem cells generated new egg cells.

Tilly said the process makes evolutionary sense. "If you look at this from an evolutionary perspective, males have sperm stem cells that continually make sperm. Because species propagation is so important, we want to make sure it's the best sperm, so don't want sperm sitting around for 60 years waiting to get used," he said. It makes no sense from an evolutionary perspective that "females will be born with all the eggs they will have and let them sit there," he noted.

Hershlag, meanwhile, said much remains to be overcome.

"Ultimately, in our field only one thing counts," he said, "and that is if you can make an egg that can make a healthy baby."

More information

The U.S. National Library of Medicine has more on how human embryos develop.

Here is the original post:
Stem Cell Finding Could Expand Women's Lifetime Supply of Eggs

Posted in Cell Medicine | Comments Off on Stem Cell Finding Could Expand Women’s Lifetime Supply of Eggs

Susan Samueli, PhD of the Susan Samueli Center for Integrative Medicine UC Irvine to Headline A2Z Health Expo in Los …

Posted: February 24, 2012 at 11:56 pm

LOS ANGELES, CA--(Marketwire -02/24/12)- A2Z Health Expo today announced it will hold its 5th annual Health Expo at the Skirball Cultural Center in Los Angeles, CA on Thursday, March 22, 2012 from 4pm to 10pm. According to Dr. Ben Drillings, Director, the keynote speaker for the event will be the co-founder of the Samueli Foundation, Susan Samueli, PhD. Mrs. Samueli serves on the Board and Advisory Board of the Susan Samueli Center for Integrated Medicine (SSCIM) at UC Irvine. SSCIM promotes integrative medicine by providing education, scientific research and a model of clinical care that emphasizes healing of the whole person. Mrs. Samueli was honored with the UCI Medal in March 2000, the 2002 Ellen Cooperman Angel Award Recipient from the John Wayne Cancer Institute and the 2005 General William Lyon Crystal Vision Philanthropy Award from the Orangewood Children's Foundation. In 2006, Susan and Henry Samueli became the owners of the NHL franchise the Anaheim Ducks. The topic of Mrs. Samueli at the expo is: "Integrated Clinic in the 21st Century: Innovations, New Models & Challenges."

The A2Z Health Expo event is focusing on bringing together healthcare professionals, philanthropists, academicians, that are interested in learning more about the integrated clinic model. The expo aims to build a network relationship and sharing of ideas within the health community. Attendees include MDs, Chiropractors, Massage Therapists, Nutritionists, Schools & Spa owners, and general public.

Joining Mrs. Samueli are a bevy of prestigious speakers: Kerry Crofton, PhD., the author of the award-winning book, Wireless Radiation Rescue, and co-founder and executive Director of the International Advisory Board Doctors for Safer Schools; Dr. Nathan Newman, innovator of Stem Cell Lift -- cutting edge cosmetic surgery, without cutting;
And Ms. Alexa Zaledonis, who is the current chair of the National Certification Board for Therapeutic Massage & Bodywork as well as the owner of Even Keel Wellness Spa.

Dr. Drillings is urging the healthcare community to come and learn about the integrated clinic model. This is a must see expo!

The Skirball Cultural Center is located at 2701 N. Sepulveda Blvd., Los Angeles, CA 90049. To register to the event, please visit http://www.a2zhealthexpo.com or email us at expo@a2zhealthexpo.com or call (818) 700-0286.

Continued here:
Susan Samueli, PhD of the Susan Samueli Center for Integrative Medicine UC Irvine to Headline A2Z Health Expo in Los ...

Posted in Cell Medicine | Comments Off on Susan Samueli, PhD of the Susan Samueli Center for Integrative Medicine UC Irvine to Headline A2Z Health Expo in Los …

First researcher joins The Jackson Lab for Genomic Medicine in Conn.

Posted: February 24, 2012 at 5:44 pm

Bar Harbor – Yijun Ruan, Ph.D., an American geneticist who has pioneered new techniques to sequence and map DNA to better understand cancer growth and stem cell properties, will be the first scientist to join the new Jackson Laboratory for Genomic Medicine (JAX Genomic Medicine) in Farmington, Conn.

Ruan is currently associate director and senior group leader at the Genome Institute of Singapore and professor of biochemistry at the National University of Singapore. He is also an investigator with the Encyclopedia of DNA Elements (ENCODE) project, an international consortium of research groups funded by the National Human Genome Research Institute.
Ruan said he was attracted by The Jackson Laboratory’s famously collaborative research environment, and plans to “take a community approach to tackle genomic questions through intensive collaboration.” Through innovating new technologies and studying how the human and mouse genomes are regulated, he said his goal is to translate research findings into personalized medicine. Ruan has also been appointed director of JAX Genomic Sciences, and will be bringing his current research program and team with him to JAX Genomic Medicine.
JAX Genomic Medicine will unite doctors, patients, scientists and industry to find new ways to tailor disease diagnosis, prevention and treatment to each person’s unique genetic makeup, or genome. Ruan and other recruits will begin initial operations this year in leased space while a 173,000-square-foot permanent facility is designed and built. Construction will begin in 2013, and the new facility will open in 2014.
“Yijun’s broad interests in genome biology, coupled with his innovative approach to developing new research techniques, make him an ideal member of the new JAX Genomic Medicine research team,” said Bob Braun, Ph.D., Jackson’s associate director and chair of research.
After earning BS and MS degrees in microbiology from Huazhong Agricultural University in Wuhan, China, Ruan obtained his Ph.D. in plant molecular biology from the University of Maryland, College Park, where he also conducted postgraduate research. Following scientific appointments at Monsanto Co. in St. Louis and Large Scale Biology Corp. in Vacaville, Calif., Ruan was recruited to the Genome Institute of Singapore (GIS) in 2002. Edison Liu, M.D., former director of GIS and now president and CEO of The Jackson Laboratory, credits Ruan for building the institute’s state-of-the-art genomic technology platforms and its award-winning genome biology programs.
Ruan is an author of 70 research papers and holds patents in Japan, Singapore and the United Kingdom for the DNA analysis techniques he helped to develop. A U.S. citizen, Ruan is married and has two children.
In addition to recruiting research faculty, JAX Genomic Medicine is currently hiring a site director, science coordinator, senior human resources manager, facilities manager and senior financial analyst in Connecticut. Job announcements are on The Jackson Laboratory’s website at http://www.jax.org/careers/connecticut.html.
Braun notes that The Jackson Laboratory is expanding the research faculty at its headquarters campus in Bar Harbor, Maine, as well as recruiting faculty in Connecticut.
The Jackson Laboratory is an independent, nonprofit biomedical research institution and National Cancer Institute-designated Cancer Center based in Bar Harbor, Maine, with a facility in Sacramento, Calif., afuture institute in Farmington, Conn., and a total staff of about 1,400. Its mission is to discover the genetic basis for preventing, treating and curing human disease, and to enable research and education for the global biomedical community.

For more health news, pick up a copy of the Mount Desert Islander.

Read the original here:
First researcher joins The Jackson Lab for Genomic Medicine in Conn.

Posted in Cell Medicine | Comments Off on First researcher joins The Jackson Lab for Genomic Medicine in Conn.

Editor’s move sparks backlash

Posted: February 21, 2012 at 6:13 pm

Bioethicist Glenn McGee’s new job raised questions of conflict of interest at the journal he founded.

J. WILSON/KRT/NEWSCOM

The field of bioethics is embroiled in a period of soul-searching, sparked by a startling career move by one of its biggest names.

Glenn McGee is the editor-in-chief of the American Journal of Bioethics (AJOB), the most cited bioethics journal, which he founded in 1999. Since December 2011, he has also been president for ethics and strategic initiatives at CellTex Therapeutics in Houston, Texas, a controversial company involved in providing customers with unproven stem-cell therapies. A CellTex press release says that “Dr McGee’s responsibilities will include ensuring that all of the firm’s work, centered on adult stem cells, will meet the highest ethical standards of the medical and scientific communities.”

Although McGee has said he will leave the journal on 1 March, many bioethicists have criticized him, the journal’s editorial board and its publisher, London-based Taylor and Francis. They argue that in holding both posts, McGee has a conflict of interest between his responsibilities to the journal and his new employer’s desire to promote the clinical application of stem-cell treatments that are not approved by the US Food and Drug Administration.

“Imagine if the Editor of the New England Journal of Medicine took a job as Vice President at Merck, and the Mass Medical Society asked him to stay on as Editor, opining that the conflicts of interest would be manageable. One might rightly wonder, ‘What are these people smoking?’,” says John Lantos, director of the Children’s Mercy Bioethics Center in Kansas City, Missouri, and a past president of the American Society for Bioethics and Humanities.

More broadly, bioethicists are questioning whether it can ever be acceptable to work for companies, which, they argue, may be using the appointment to present a veneer of ethical probity. The episode brings to a head concerns that have emerged among bioethicists over the past decade, says Insoo Hyun, a stem-cell bioethicist at Case Western Reserve University in Cleveland, Ohio. “It’s a perfect storm,” he says.

McGee is a leading voice on one side of the debate, arguing that bioethics must have practical relevance. For the past three years he has been chair of bioethics at the non-profit Center for Practical Bioethics in Kansas City, where he ran a course for those who might go on to chair hospital ethics committees or serve as ethical advisers to corporations.

But during McGee’s tenure as editor-in-chief of the AJOB, four editors are known to have resigned from the editorial board because of differences in opinion over how the journal handles conflicts of interest. Two left this month, including Lantos, who wrote on his blog that he will no longer work with the journal because of McGee’s simultaneous employment at the AJOB and CellTex, and frustration over the lack of a clear conflict-of-interest policy at the AJOB. In response to Nature’s questions about the situation, Taylor and Francis responded that it “is grateful for Dr McGee’s editorship of AJOB” and “supportive of Glenn’s decision to step down”.

On 17 February, McGee announced that he is merely acting in an advisory capacity at the journal until 1 March, when its new editors-in-chief take over. They are David Magnus, director of the Center for Biomedical Ethics at Stanford University, California, and Summer Johnson McGee, director of graduate studies at the Center for Practical Bioethics and the journal’s current executive editor. She is also Glenn McGee’s wife.

“Mainstream bioethics is no longer speaking truth to power.”

Responding to questions from Nature, Summer Johnson McGee says that the journal has a conflict-of-interest policy that requires editors to withdraw from reviewing a manuscript if they perceive a conflict. She calls allegations that her appointment results from her relationship with her husband “baseless and sexist”. “David Magnus and I were hired by our publisher, not by my husband.” Magnus says that at least a dozen editorial board members have supported his and Summer Johnson McGee’s appointments. Two even indicated that Glenn McGee should have been able to retain an advisory or editorial role.

Other bioethicists’ blogs and Twitter feeds about the episode have expressed concerns, however. Leigh Turner of the University of Minnesota, Minneapolis, called on the entire editorial board of the AJOB to resign for allowing the situation to persist. And many say that McGee’s move illustrates a broader problem. “Mainstream bioethics is no longer speaking truth to power,” complains Jan Helge Solbakk at the University of Oslo. “Instead it has become the handmaiden of the medico-industrial complex, and of bioscience and technology.”

So how should companies get their advice on bioethics? Magnus never takes cash from industry for advising or speaking — “I’m a hardass about that” — but he believes that bioethicists can work for industry as long as they give up their academic positions, including posts on journal editorial boards.

Working for a respected company may be acceptable to some bioethicists, but McGee’s new employer comes with a great deal of baggage. CellTex, which was founded last year and as yet has no website, licenses stem-cell technology from Seoul-based RNL Bio. The South Korean company has made a business out of taking fat cells from people, processing them in a way that they say increases the number of mesenchymal stem cells, and then reinjecting them in an effort to treat conditions such as spinal cord injury.

McGee already had a connection with RNL Bio. In 2010, two patients died following injections of RNL’s cells. McGee, working for stem-cell lobby group the International Cellular Medicine Society, based in Salem, Oregon, helped to conduct an investigation into the company. This concluded that only one of the two cases was likely to be related to the injections, and because the patient understood the risk the company was not culpable.

Jin Han Hong, the then president of RNL’s US subsidiary, admitted in 2010 that there was no clinical-trial evidence proving that these treatments are effective (Nature 468, 485; 2010). As treatment with RNL’s stem cells is not approved in the United States or South Korea, for the procedures the company sends patients to China or Japan, where regulations are less strictly enforced. Using RNL’s methods, CellTex is banking stem cells that have gone on to be used in a number of patients, including Rick Perry, governor of Texas (Nature 477, 377–378; 2011). CellTex says that it does not conduct medical procedures itself.

When Nature contacted McGee to put the criticisms to him, he directed us to previous statements indicating that he wants to put CellTex on firmer ethical ground by having it conduct clinical trials that meet standards set by the International Society for Stem Cell Research, based in Deerfield, Illinois, which represents most mainstream stem-cell researchers around the world.

Hyun warns that working directly for business can be fraught with danger, however good a bioethicist’s intentions. In 2005, he helped to craft the informed consent procedure for egg donations used in a cloning procedure by disgraced Korean stem-cell scientist Woo Suk Hwang. Following Hwang’s claim, later proved fraudulent, that he had cloned human embryos and harvested stem cells from them, it emerged that he had ignored the consent procedure for egg donations (Nature 438, 536–537; 2005), leading to embarrassment for Hyun.

“I know first hand how difficult it is to separate conflict of interest — to maintain the role of bioethicist,” says Hyun. “I know you need to not be too chummy with enterprises trying to speed ahead in stem cells.”

Excerpt from:
Editor’s move sparks backlash

Posted in Cell Medicine | Comments Off on Editor’s move sparks backlash

Novo Energies Corporation Announces Dr. Michael Har-Noy’s Seminar to The Johns Hopkins Institute for Cell Engineering

Posted: February 21, 2012 at 2:57 pm

NEW YORK, NY--(Marketwire -02/21/12)- Novo Energies Corporation ("Novo") (OTC.BB: NVNC.OB - News) today announced that Dr. Michael Har-Noy, Founder and Chief Executive Officer of Immunovative Therapies, Ltd. ("Immunovative"), was invited to present Immunovative's technologies to The Johns Hopkins Institute for Cell Engineering on February 14, 2012.

Immunovative is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer and has 10 U.S. patents granted, 15 U.S. patents pending, 26 corresponding applications pending internationally and two experimental product candidates for the treatment of cancer in clinical development: AlloStim™ and AlloVax™.

The Johns Hopkins Institute for Cell Engineering represents the stem cell and immunotherapy research effort at The Johns Hopkins University School of Medicine, where faculty, fellows, postdocs and students and staff study some of the most exciting problems in stem cell science and immunotherapy today.

On December 15, 2011, Novo signed an exclusive License Agreement with Immunovative, pursuant to which Novo has been granted an exclusive, worldwide license to commercialize any products covered under Immunovative's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including AlloStim™ and AlloVax™. Novo intends to change its name and symbol to better reflect its new direction.

About Immunovative Therapies, Ltd.:

Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: http://www.immunovative.co.il

About Novo Energies Corporation:

Novo Energies Corporation is in the process of transforming into the cancer therapy area and intends to institute a name and symbol change to better reflect the new direction of the Company.

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2011, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

View post:
Novo Energies Corporation Announces Dr. Michael Har-Noy's Seminar to The Johns Hopkins Institute for Cell Engineering

Posted in Cell Medicine | Comments Off on Novo Energies Corporation Announces Dr. Michael Har-Noy’s Seminar to The Johns Hopkins Institute for Cell Engineering

LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

Posted: February 21, 2012 at 10:08 am

To: HEALTH AND NATIONAL EDITORS

VIRGINIA BEACH, Va., Feb. 20, 2012 /PRNewswire-USNewswire/ -- Rony Thomas, President and CEO of LifeNet Health, is presenting at the 7th Annual Stem Cell Summit in New York City on February 21, 2012. Mr. Thomas will be presenting on LifeNet Health's broad offerings of current and future regenerative biologic-based products. Mr. Thomas will also focus on the multiple new capabilities and technology platforms of the LifeNet Health Institute of Regenerative Medicine.

(Photo: http://photos.prnewswire.com/prnh/20120220/DC55479)

"The use of a variety of forms of donated tissues has worked for decades to save lives and restore health in many surgical disciplines. Now we are on the cusp of developing cellular therapies, tissue engineering and new medical applications for allografts to treat disease and assist in the development of lifesaving drugs. The opening of the LifeNet Health Institute of Regenerative Medicine this year will signal our commitment to future development in the cellular therapies arena," stated Mr. Thomas. Thomas will further focus on two new areas of development; Human Basement Membranes in zeno-free culture of consented Human mRNA Reprogrammed Induced Pluripotent Stem Cells and Induced Pluripotent Stem Cells (iPSc) derived using non-integrating mRNA reprogramming technology from fully consented queryable human donor banked system.

Mr. Thomas was also recently invited to and attended a White House Summit to discuss ways in which technology and innovation can drive employment opportunities for Virginia, where LifeNet Health and the Institute are located. The meeting of key CEOs with the Obama Administration was to gain insight and input on the job market and technology as a driver to local, state, and national economies. Thomas stated, "Our foray into regenerative medicine should not only impact our state and local economy, but provide medical benefits to patients and drug companies across the globe."

The annual Stem Cell Summit brings key leaders in the medical, scientific and business innovators in this growing space of technology and regenerative medicine. LifeNet Health is pleased to be joining the Summit for the first time in 2012 as they look for key partnerships and collaboration in the discovery of cell-based therapies for a broad spectrum of medical applications in orthopedics, trauma, dental, craniomaxillofacial (CMF), plastics, and cardiovascular surgery.

LifeNet Health helps to save lives and restore health for thousands of patients each year. We are the world's most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies--a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.

The LifeNet Health Institute of Regenerative Medicine is a division of LifeNet Health located in Virginia Beach, Virginia. The Institute's labs will be expanding as new facilities are under construction and planned to be completed in the fall of 2012. Once completed and fully functional, the Institute will house over 50 medical, scientific, and research staff members. The focus will be on the science of developing regenerative medicine products for patients all over the world, and will serve as a global center of excellence for research and development focused on cellular therapies, tissue engineering, and new medical applications for allografts to maximize the gift of donation.

SOURCE LifeNet Health

-0-

The rest is here:
LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

Posted in Cell Medicine | Comments Off on LifeNet Health is Presenting at the 7th Annual Stem Cell Summit in New York on February 21, 2012

Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Posted: February 19, 2012 at 4:00 pm

EDMOND, OK--(Marketwire -02/19/12)- The team of veterinarians at White Oaks Veterinary Clinic in Edmond announced that the animal hospital is now offering pet stem cell therapy. This new regenerative medicine for pets helps animals suffering from degenerative joint disease or arthritis. Based on the research and technology provided by a company called Stemlogix, White Oaks Veterinary Clinic can now offer affordable, same-day stem cell therapy to dogs suffering from these debilitating conditions. The Stemlogix technology enables the Edmond veterinarians to extract adult stem cells from a pet's own body fat, virtually eliminating the risk of rejection or negative reaction.

"I see far too many otherwise healthy pets at our veterinary clinic that have been hobbled by the effects of arthritis," Dr. Jennifer Bianchi said. "We're thrilled to be able to offer this holistic solution which harnesses the pet's own healing power to aid in the pain relief process. Our main goal with stem cell therapy is to reduce long-term inflammation and slow the progression of cartilage damage. The motto at our veterinary hospital is, 'Quality service at a great value.' Being able to provide stem cell transplants in about two hours at an affordable rate helps us live up to that promise and makes me happy to think of the pets we'll be able to help move freely again."

The veterinary hospital now has an on-site stem cell laboratory for producing stem cells. The on-site lab allows for immediate processing after extraction as the stem cells have a limited lifespan outside of the pet's body. Once the fat cells have been procured from the pet, the stem cells are isolated and returned back to the host body within ninety minutes. Stemlogix promotes this therapy as being able to relieve pain and increase range of motion in pets suffering with joint pain, arthritis, tendon and ligament damage, hip dysplasia and cartilage damage.

Once implanted, stem cells have the ability to stimulate regeneration, reduce pain and inflammation, and assist in the repair of damaged tissue. They can also differentiate into other cell types such as tendon, cartilage, bone, and ligament, which may further aid the repair process. The Edmond veterinarian says that pain relief can be expected within a few days to a few weeks. Pet owners are cautioned to gradually allow their pets to experience increased activity so as not to interfere with the healing process.

As a holistic veterinarian, White Oaks Veterinary Clinic combines natural healing techniques, such as pet acupuncture, with traditional veterinary medical services. The animal hospital was founded in 1997 and is currently practicing out of a 6500 square foot facility. Equine vet, Dr. Mark Bianchi, offers general and advanced services such as surgery, equine dentistry, lameness evaluations and reproduction consultations.

White Oaks Veterinary Clinic is located at 131 W. Waterloo Rd. Further information on the animal hospital or pet stem cell therapy may be obtained by visiting the website at http://www.whiteoaksvet.com.

Read the original:
Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Posted in Cell Medicine | Comments Off on Edmond Veterinary Hospital Offers Pet Stem Cell Therapy for Arthritis

Stem-cell scientists find right chemistry

Posted: February 19, 2012 at 9:20 am

The day – Valentine’s Day, as it happened – began in a whirl of coffee cups, bustling dogs and homework, then a brisk walk around the block – in other words, business as usual for a UC Irvine couple who are a high-profile science team engaged in cutting-edge stem-cell research.

Brian Cummings and Aileen Anderson, whose stem-cell treatment for spinal cord injury is being tested on patients in Switzerland, say their office – only a short walk from their home on the UCI campus – has a family feel as well.

At UCI’s recently constructed Stem Cell Research Center, they supervise a crew of young students and technicians whose bond with their mentors is so close that they call themselves the “Andermings.”

“I suppose it’s like having an orphanage,” Cummings joked as he prepared for the day ahead.

It would include a lengthy meeting with the Andermings on how best to grow human embryonic stem cells without animal-cell contamination, a critique of a doctoral candidate’s presentation of potentially significant new findings and a session with Alzheimer’s researchers at an institute called UCI MIND.

But first, Cummings, Anderson and their two dogs – Chesapeake and Indiana – had to get the couple’s 6-year-old daughter, Camryn, to school.

After Camryn finished her homework (completed strategically a day in advance, leaving more time for afternoon play), they took the long way round to the Montessori school, also easy walking distance from their home.

Along the way, they encountered another faculty couple, from the German department, and their dog. They stopped with Camryn, giggling as the dogs rolled and tumbled on a neighbor’s lawn.

•••

Cummings, 47, and Anderson, 45, together since they were both undergrads at the University of Illinois, say living and working with each other comes naturally.

“People say, ‘Do I need a break from her?’ ” Cummings said as he wrangled the dogs.

“More people say, ‘Do you need a break from him?’ ” Anderson replied.

Later, the conversation transitions into a science meeting as the two take the 20-minute walk past UCI’s Ecological Preserve and into the Sue and Bill Gross Stem Cell Research Center. The energy-efficient building, with an open design to encourage chance meetings among scientists, houses a roster of high-powered researchers as well as their experimental subjects: rodents.

The center was seeded by $27 million in state stem-cell funding and $10 million from donors Bill and Sue Gross. The building was completed in 2010.

Now, researchers working there cultivate lines of human embryonic stem cells that can grow into a variety of cell types, from brain cells to liver and heart cells.

The ability to coax stem cells into many forms – and with it the potential to treat Alzheimer’s, paralysis and a long list of diseases – is fueling an explosion of research around the nation and across the state.

Anderson and Cummings showed that their stem-cell treatment, using cells derived from aborted fetuses, allowed partially paralyzed rats to walk again. The rat’s recovery was revealed in a dramatic before-and-after video.

So far, the human trial of the treatment in Switzerland is showing no ill effects on patients, Cummings said.

But stem-cell research is buffeted by political controversy, funding uncertainties and, sometimes, attacks by stem-cell research opponents.

The trial of the treatment developed by Cummings and Anderson with their collaborators, StemCells Inc., was the first of its kind in the world when it was announced in 2010.

In some ways, that made the family – and their team – a target.

Concerns about possible intruders prompted the couple to place a camera at their front door. Cummings’ tires have been slashed, he said, though he doesn’t know if that was the work of people who oppose the harvesting of human embryonic stem cells, animal-rights activists (angered by experiments on rodents) or perhaps a disgruntled student.

At the moment, Cummings and Anderson are running five research programs and leading 17 researchers. All of it is funded by $2.2 million in grants, much of it from California Institute for Regenerative Medicine, or CIRM.

Created by voter initiative – Proposition 71 in 2004 – CIRM is California’s $3 billion answer to federal restrictions on funding for stem-cell research. Those restrictions were started by the Bush administration and eased, but not eliminated, under President Obama.

Cummings said opposition to their research is based, in part, on incorrect assumptions.

A big one is that the research involves the destruction of embryos. In reality, they work with balls of cells created at an earlier stage of human development, called blastocysts – a distinction many opponents do not draw.

“Embryonic stem cells don’t come from embryos,” he said. “And they never have.”

The raw material comes from fertility clinics and otherwise would be discarded.

Cummings says those who say that such research is immoral have it wrong.

“The argument is backward,” he said. “It’s immoral to throw away this stuff and not use it to help someone.”

••

During their meeting with the Andermings, project leader Hal Nguyen described the group’s plan to grow a series of stem-cell cultures and check a compelling question: Is some of a stem cell’s transformation guided by the microscopic environment in which it dwells, or is it entirely dictated by the cell’s internal workings?

“The plan is in the email,” Nguyen told Anderson.

“Dude, I have 400 emails,” Anderson said.

The group’s task was meant to answer a classic nature-nurture question, Anderson said. In this case, “nature” is the DNA coding in the stem cell itself, while “nurture” is the cellular environment, with all its floating nutrients and chemical signals.

“Will that environment, the extrinsic factor, trump anything the cell can do?” Anderson had wondered earlier. “Or is the intrinsic programming of the cell the principal determinant? Is that the main driving factor?”

Cummings stood by in the tiny meeting room while the researchers batted around their questions and answers. He said Anderson, a spinal cord specialist, was the expert in this arena, though he couldn’t help piping in during a discussion of the medium in which the cells would be grown.

“You’re comparing two different medias, too?” Cummings asked.

“We all know what we’re talking about,” Anderson told him. “Don’t interrupt.”

Then it was on to a larger, mostly empty meeting room where Sheri Peterson, a doctoral candidate, wanted to test her presentation on Cummings and Anderson.

Her eventual target is an advancement committee that will determine her future. The presentation will be crucial in her quest for a Ph.D.

Peterson ran through an array of slides projected on a large screen to reveal her findings. Inflammation of damaged tissue being regenerated in rats, she said, might be eased or worsened simply by manipulating proteins surrounding the regenerating cells.

Again, the topic was in Anderson’s wheelhouse.

“My notes said, ‘Nicely done,’ ” Cummings told Peterson.

“He’s not an aficionado,” Anderson said.

The husband-and-wife researchers then provided her with a detailed, slide-by-slide critique.

•••

Cummings’ expertise centers on traumatic brain injury. But he also is an expert at the complex task of marshaling grant funding. On his office wall, a whiteboard densely covered with writing tells the story: Cummings must police incoming and outgoing grants like an air traffic controller, timing the grants and the work they fund to match years of employment for graduate students and staff members.

The grants come and go over months and years, and so do the students and staff. Get the timing wrong, and you might have funding with no researchers, or researchers with nothing to do.

“At UCI, I’m like a small-business owner,” Cummings said.

Over a hasty lunch in his office (cold sandwiches grabbed during a trip, with Anderson, to a nearby campus snack shop), Cummings spoke of the merging of home and office life.

Writing up grant requests takes up both researchers’ time. Often, as they write, Camryn is playing in the background, whether at home or at the office. And research collaborators can show up wanting to conduct interviews at any time, holidays included.

“I did draw a line in the sand at Christmas Eve,” Anderson said.

Cummings knows such stress has driven other husband-and-wife teams into open conflict. But that just isn’t his and Anderson’s style. In fact, he said, keeping a scientific perspective, even at home, might help keep things calm.

“There’s no need to be yelling and shouting at each other because we don’t think that way,” he said. “You’re supposed to believe nothing until you prove it.”

That doesn’t mean they don’t differ, sometimes strongly, over scientific details.

“They don’t always agree with each other, and that’s good,” said Brittany Greer, an intern in their lab and an Anderming.

Nurturing the students and young scientists is part of the pleasure of doing science for both halves of the research couple, Anderson said.

“You start to look at this crowd of people as your second family,” she said. “They’re your kids. That is fun and rewarding for sure.”

See the original post:
Stem-cell scientists find right chemistry

Posted in Cell Medicine | Comments Off on Stem-cell scientists find right chemistry

Histogenics to Present at 7th Annual New York Stem Cell Summit

Posted: February 17, 2012 at 8:16 am

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics Corporation, a privately held regenerative medicine company, today announced that the Company will present at the 7th Annual New York Stem Cell Summit on February 21st at Bridgewaters New York City. Kirk Andriano, Ph.D., Vice President of Research and Development for Histogenics, will speak about current and future cell therapies being developed by the Company as it works toward commercialization. Lead candidates include NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix designed to stimulate cartilage repair in a simple, one-step procedure. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met and a favorable safety profile was demonstrated.

Dr. Andriano earned his BS in chemistry and biology from Utah State University and his MS and Ph.D. in bioengineering from the University of Utah. Prior to his work at Histogenics, he was the Chief Technology Officer for ProChon Biotech, Ltd. which was acquired by Histogenics in May 2011.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopaedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials of its NeoCart autologous tissue implant and is currently in a Phase 3 IND clinical study. Based in Waltham, Massachusetts, the company is privately held. For more information, visit http://www.histogenics.com.

See original here:
Histogenics to Present at 7th Annual New York Stem Cell Summit

Posted in Cell Medicine | Comments Off on Histogenics to Present at 7th Annual New York Stem Cell Summit

Page 131«..1020..130131132133..140..»